UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of May 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: May 23,
2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit 99.1
Indivior PLC (the
'Company')
Result of General Meeting
May 23, 2024
The Company announces the voting result of its General Meeting,
held earlier today at the offices of Freshfields Bruckhaus
Deringer, 100 Bishopsgate, London EC2P 2SR.
The resolution set out in the Notice of Meeting circulated to
shareholders and published on May 3, 2024 was duly passed by
shareholders by way of a poll.
The voting result, incorporating proxy votes lodged in advance of
the General Meeting, is set out below and will be made available on
the Company's website at http://www.indivior.com/en/investors/shareholder-information.
|
RESOLUTION
|
VOTES FOR
|
%
|
VOTES AGAINST
|
%
|
VOTES TOTAL
|
% of ISC VOTED1
|
VOTES WITHHELD2
|
|
To
approve the transfer of the Company's category of equity share
listing on the London Stock Exchange plc from a Premium Listing to
a Standard Listing
|
86,261,468
|
96.94
|
2,718,492
|
3.06%
|
88,979,960
|
65.86
|
9,491
|
Graham Hetherington, Chair, said:
'We are pleased with the strong support received from shareholders
at today's General Meeting to enable Indivior to move its primary
listing to the Nasdaq Stock Market. We believe that this move will
better align with the Group's current and future growth
opportunities, attract more U.S. investors and analysts, allow for
inclusion in U.S. indices over time and better reflect the growing
proportion of our investors that are based in the U.S.
We expect the transfer of the primary listing will become effective
on Thursday June 27, 2024. The Board intends to maintain Indivior's
U.K. listing as a secondary listing following the
transfer for as long as it is
considered to be in the best interests of Indivior and Indivior
shareholders as a whole.'
Notes:
1.
As at the close of business on May 21, 2024, the total number
of ordinary shares of US$0.50 eligible to be voted at the GM was
135,096,376. Therefore, the total voting rights in the
Company as at that time was 135,096,376.
2.
A vote withheld is not a vote in law and is not counted in the
calculation of the votes for or against a resolution.
A copy of the resolution will be submitted to the National Storage
Mechanism and will be available to
view at https://data.fca.org.uk/#/nsm/nationalstoragemechanism in
due course.
Computershare Investor Services PLC acted as scrutineer of the poll
on the resolution.
Key
Contacts:
Jason Thompson
VP, Investor Relations
+1 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
+1 804-263-3978 or timothy.owens@indivior.com
Kathryn Hudson
Company Secretary
+44 (0)1753 423940 or kathryn.hudson@indivior.com
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD) and serious mental illnesses. Our vision is that
all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
SUD. Indivior is dedicated to transforming SUD from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this
category and potentially address other chronic conditions and
co-occurring disorders of SUD, including alcohol use disorder and
cannabis use disorder. Headquartered in the United States in
Richmond, VA, Indivior employs over 1,100 individuals globally and
its portfolio of products is available in 37 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/
company/indivior.
Important Cautionary Note Regarding Forward-Looking
Statements
This announcement contains
certain statements that are forward-looking. Forward-looking
statements include, among other things, statements regarding our
intention to transfer our primary listing to Nasdaq while
maintaining a secondary listing in the U.K., and the expected
timing and potential benefits of such transfer; expected future
growth; and other statements containing the words "believe,"
"anticipate," "plan," "expect," "intend," "estimate," "forecast,"
"strategy," "target," "guidance," "outlook," "potential,"
"project," "priority," "may," "will," "should," "would," "could,"
"can," "outlook," "guidance," the negatives thereof, and variations
thereon and similar expressions. By their nature, forward-looking
statements involve risks and uncertainties as they relate to events
or circumstances that may or may not occur in the
future.
Actual results may differ materially from those expressed or
implied in such statements because they relate to future events.
Various factors may cause differences between Indivior's
expectations and actual results, including, among others, the
material risks described in the most recent Indivior PLC Annual
Report and in subsequent releases; the substantial litigation and
ongoing investigations to which we are or may become a party; our
reliance on third parties to manufacture commercial supplies of
most of our products, conduct our clinical trials and at times to
collaborate on products in our pipeline; our ability to comply with
legal and regulatory settlements, healthcare laws and regulations,
requirements imposed by regulatory agencies and payment and
reporting obligations under government pricing programs; risks
related to the manufacture and distribution of our products, most
of which contain controlled substances; market acceptance of our
products as well as our ability to commercialize our products and
compete with other market participants; competition; the
uncertainties related to the development of new products, including
through acquisitions, and the related regulatory approval process;
our dependence on third-party payors for the reimbursement of our
products and the increasing focus on pricing and competition in our
industry; unintended side effects caused by the clinical study or
commercial use of our products; our ability to successfully execute
acquisitions, partnerships, joint ventures, dispositions or other
strategic acquisitions; our ability to protect our intellectual
property rights and the substantial cost of litigation or other
proceedings related to intellectual property rights; the risks
related to product liability claims or product recalls; the
significant amount of laws and regulations that we are subject to,
including due to the international nature of our business;
macroeconomic trends and other global developments such as armed
conflicts and pandemics; the terms of our debt instruments, changes
in our credit ratings and our ability to service our indebtedness
and other obligations as they come due; changes in applicable tax
rate or tax rules, regulations or interpretations and our ability
to realize our deferred tax assets; and volatility in our share
price due to factors unrelated to our operating performance or that
may result from the potential move of our primary listing to the
U.S.
Forward-looking statements speak only as of the date that they are
made and should be regarded solely as our current plans, estimates
and beliefs. Except as required by law, we do not undertake and
specifically decline any obligation to update, republish or revise
forward-looking statements to reflect future events or
circumstances or to reflect the occurrences of unanticipated
events.
Indivior PLC's Legal Entity Identifier code is
213800V3NCQTY7IED471.
Indivior (NASDAQ:INDV)
Historical Stock Chart
From May 2024 to Jun 2024
Indivior (NASDAQ:INDV)
Historical Stock Chart
From Jun 2023 to Jun 2024
